Insulin-sensitive obese children display a favorable metabolic profile

Rade Vukovic1, Katarina Mitrovic, Tatjana Milenkovic

  • 1Department of Endocrinology, Mother and Child Health Care Institute of Serbia "Dr Vukan Cupic", 11070, Belgrade, Serbia. radevukovic9@gmail.com

Insights

Insulin sensitivity, measured by HOMA-IR, is linked to a healthier metabolic profile in obese children. Lower insulin resistance indicates better metabolic health, supporting further research in childhood obesity.

Area of Science:

  • Pediatric Endocrinology
  • Metabolic Health
  • Obesity Research

Background:

  • The metabolically healthy obese (MHO) phenomenon is primarily studied in adults, lacking standardized criteria for children.
  • Childhood obesity is a growing concern with potential long-term metabolic consequences.

Purpose of the Study:

  • To investigate the association between preserved insulin sensitivity (low HOMA-IR) and a favorable metabolic profile in obese children.
  • To determine if insulin sensitivity can serve as a marker for metabolic health in pediatric obesity.

Main Methods:

  • A cohort of 248 obese children and adolescents (aged 5.9-18.9 years) was analyzed.
  • Participants were divided into quartiles based on Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) index.
  • Insulin-sensitive (low HOMA-IR) and insulin-resistant (high HOMA-IR) groups were compared for metabolic parameters.

Main Results:

  • Children with lower HOMA-IR (insulin-sensitive group) exhibited significantly better metabolic profiles.
  • This included lower LDL cholesterol, triglycerides, and transaminases, and higher HDL cholesterol.
  • Insulin-sensitive children were less likely to have impaired fasting glucose or impaired glucose tolerance.

Conclusions:

  • Lower HOMA-IR values are significantly associated with a favorable metabolic profile in obese children.
  • These findings in children mirror those in the adult population regarding insulin resistance and metabolic health.
  • Further longitudinal studies are needed to understand insulin resistance development in childhood obesity.
Abstract

Related Concept Videos

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Carbohydrate Metabolism01:36

Carbohydrate Metabolism

Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in the...
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...